



Adjuvant systemic therapy		
P001	Scalp cooling system for breast cancer patients treated by adjuvant or neo-adjuvant chemotherapy.	Mitsuchika Hosoda
P003	ROSE trial: A prospective non-interventional study to assess the quality of life (QoL) of premenopausal patients with early breast cancer receiving triptorelin as ovarian function suppression	Elisabetta Munzone
P004	Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer : a multicenter, open-label, phase 2 trial	Feilin Cao
P005	Impact of oral bacterial counts on febrile neutropenia during breast cancer chemotherapy	Kanako Suzuki
P006	Randomized Phase II trial evaluating three anti-diarrhoeal prophylaxis strategies in patients with HER2+ / HR+ early breast cancer treated with extended adjuvant neratinib (DIANER GEICAM/2018-06)	Santiago González-Santiago
P007	Tamoxifen reduced breast cancer recurrence in women with DCIS who underwent mastectomy	Netchanok Saesim
P008	Real-world analysis of the clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage node positive breast cancer in Ireland	Iseult M Browne
P009	A real-world prospective observational multi-national study in adult patients with breast cancer treated with extended adjuvant neratinib: NERLYFE study	Nadia Harbeck
P010	Retrospective modeling of adherence to endocrine therapy in early breast cancer using real-world claims data	Dominik Dannehl
P011	Utility of oncotype in premenopausal women with hormonal receptor (hr) positive her2 negative early breast cancer	Laura Arbonés Cid
P012	Survival outcomes and toxicities of adjuvant docetaxel-cyclophosphamide for four cycles in node negative triple negative and HER2 positive Chinese breast cancer patients: A 10 year follow up study	Henry C. Y. Wong
P014	Interim analysis of ELEANOR (n=200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+ and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib	Rupert Bartsch
P015	Breast Cancer patient selection for Extended Endocrine Therapy in the IDEAL trial by the 70-gene MammaPrint Test can prevent overtreatment and associated adverse events	Miranda Kleijn
P016	Patient Characteristics, Treatment and Long-term Outcomes from a Real-World Population of Early Breast Cancer Patients at High risk of Recurrence in Scotland	Peter S. Hall
P017	Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes	Miguel Martín
P018	TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator's choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy	Aditya Bardia
P019	Adjuvant chemotherapy after radical surgery and immediate reconstruction	Marta Ciaurriz Gortari
P020	Prognostic impact of adjuvant therapy after radical resection for loco-regional recurrence of breast cancer	晶子 羽山
P021	A pragmatic randomised, multicentre trial evaluating the dose timing (morning vs evening) of endocrine therapy for early breast cancer (REACT-CHRONO Study)	Marie-France Savid



Biology/Pathology/Basic Research

P022	The Relationship Between Trauma, Cancer C and Breast Cancer	Sandra Beri Addet Ntaryike
P023	Male breast cancer: a single center report of histopathological sybtypes and outcomes	Bela Mrinakova
P025	Distinguishing second primary tumor from metastasis in bilateral breast cancer using clinicopathological correlation and whole exome sequencing-based clonal relatedness analyses	Lakkana Adireklarpwong
P026	Synchronous and metachronous bilateral breast cancers: explanation of clinical differences in terms of lead-time bias and late detection	Lakkana Adireklarpwong
P027	Establishment of a Thai patient-derived breast cancer organoid biobanking for drug screening in a single medical center in Thailand	Lakkana Adireklarpwong
P029	Clinical significance of TILs components in triple negative breast carcinoma	Ana Peterko
P031	Preoperative mammocartography and mammometry for the needs of oncoplastic approaches	Ivelina Ilieva
P032	Correlation of lymphocyte infiltration (TILs) in breast cancer with prognosis	zohreh sanaat
P033	Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in-situ-hybridization	ASWIN SHANMUGALINGAM
P034	KLK4 in luminal breast cancer progression	Paulina Fuentes
P035	SLC26A9 promotes the development and stemness of triple-negative breast cancer via activating EGFR/PI3K/AKT signaling pathway	Zhiyuan Ma
P036	Classification of HER2-negative breast cancers by <i>ERBB2</i> copy number alteration status reveals molecular differences associated with chromosome 17 gene aberrations	Yoon Sim Yap
P037	EGFR overexpression is related to immunohistochemical biomarkers in breast cancer	Karim Ben Hamida
P038	Early detection of breast cancer in liquid biopsies using DNA methylation markers	Wiebren Tjalma
P039	Urine biomarkers in cancer detection: a systematic review of pre-analytical parameters and applied methods with focus on breast cancer	Stephanie Jordaens
P040	Estrogen-induced epigenetic regulation of matrisome-related genes in breast cancer	Mawieh Hamad

P041	Evaluation of an optimal cut point for the Ki-67 as a predictive recurrent marker of early-stage ER/PR positive and HER2 negative breast cancer	Pawaree Ruangprasertkun
P042	MicroRNA signature abnormalities in breast cancer cells can facilitate overexpression of chemokines and their receptors responsible for recruitment of stromal cells into tumor microenvironment	Volodymyr Halytskiy
P043	Characteristics and clinical outcomes of patients with HER2-low breast cancer	Sumire Koh
P044	A rapid point-of-care test kit for improved clinical management of patients with breast cancer and associated co-morbidities: Significance of the <i>MTHFR</i> - homocysteine pathway	Kelebogile Moremi
P045	Quantification of plasma extracellular vesicles in breast cancer patients by Single Molecule Array	Karin Favilla
P046	Whitlockite as a marker of benignity on breast microcalcifications detected by Raman Spectroscopy	Virginia Ceccarossi
P047	Adenomyoepithelioma of the breast: a case series of a rare pathology	Kelly Ruecker
P048	Association of mtDNA Copy Number Variations with Neoadjuvant in Triple Negative Breast Cancer Patients	Karin Manto
P049	Investigating the pathogenesis of poor-outcome Triple-Negative Breast Cancer	Charlotte Zoe Angel
P050	Functional characterization of genomic variants of uncertain significance (VUS) in the <i>ATM</i> gene	Sevdican Ustun Yilmaz
P051	Cost-efficacy Analysis of Use of Frozen Section Histology for Margin Assessment During Breast Conservation Surgery in Breast Cancer Patients	Vishvak Chanthar K M M
P052	Cox-2 overexpression in triple-negative invasive ductal breast cancer with correlation to clinicopathological parameters and neoangiogenesis	Liliya Volos
P053	Dysregulation of microRNA signature in breast cancer cells can facilitate overexpression of genes responsible for multiple drug resistance	Volodymyr Halytskiy
P054	Molecular characterization and the role of lymphocyte microenvironment in breast cancer	Karim Ben Hamida
P055	Morphological features of tumor angiogenesis in invasive ductal breast cancer and relationship with clinicopathological factors	Liliya Volos



Epidemiology/Prevention/Diagnosis

P056	Factors associated with long-term prognosis in the nonmetastatic HER2-positive breast cancer. A nationwide study from Korean Breast Cancer Society	Young-Joon Kang
P057	Relationship between TP 53 mutations and mammographic and ultrasonographic findings in breast cancer	Seungju Lee
P058	Outcomes of Rural Men With Breast Cancer: A Multicenter Population Based Retrospective Cohort Study	Lucas Fisher
P060	Breast cancer knowledge and screening practices amongst female in bandung city, west java, indonesia	Dodi Lumban Gaol
P061	Awareness among women regarding warning signs and effective screening methods in breast cancer.	sabin katpattil
P062	Clinico-pathological presentation and peculiar challenges of breast cancer in patients aged less than 40 years [Young Breast Cancer (YBC)]: An experience from a tertiary center of a developing nation	Zeeba Usofi
P063	First pilot breast screening project in Armenia	Artur Avetisyan
P064	Risk-reducing mastectomy in ovarian cancer patients with BRCA1/2 pathogenic variants: a comprehensive review	Eduard-Alexandru Bonci
P065	High satisfaction of women in Slovenian breast cancer screening program DORA: results of an anonymous survey	Mateja Kurir Borovčić
P067	The effect of COVID-19 pandemic on the use of Vacuum Assisted Breast Biopsy: An opportunity for change in Greece?	Maria Matiatou
P069	Barriers in the diagnosis and treatment of early breast cancer in a low middle income country (LMIC): an epidemiological profile of breast cancer patients from a teaching hospital in North India	Sanjeev Kumar Gupta
P070	An update on radiation-induced angiosarcoma of the breast: A diagnostic and management challenge	Christine Linheng Zhao
P071	Telehealth in oncofertility and Breast Cancer Patients during COVID-19: Preliminary Results of Insenoallasalute.it project	Gianluca Vanni
P072	18-SNP polygenic risk score does not improve breast cancer risk prediction in women aged 40-49 years in a Central European population with breast cancer risk below European average	Tjasa Oblak
P073	Invasive lobular breast cancer: a one- or two-sided problem (preliminary results)	Griet Verboven
P075	Evaluation of personality traits of breast cancer patients in the context of their surgical therapy	Can Tasgin
P076	Long-term outcome after omission of open surgical resection of B3-lesions of the breast	Constanze Elfgen
P077	Rapid Point of Care Germline Genetic Testing Pathway with Increased Eligibility Criteria in a Large Integrated Health Care System	Veronica Shim
P079	The 5-year Survival of Breast Cancer patients from 2011-2015: The Medical City Experience	Jennifer Frances Tañeca
P080	Fertility Preservation and Pregnancy in Breast Cancer Patients in Clinical Practice, Slovak Republic Survey	Bela Mrinakova
P081	Breast cancer in young women	Nassima Kouadri



Locally advanced disease

P082	Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center	Marijana Milovic Kovacevic
P083	Factors relating to locally advanced breast cancer in rural areas	Nawin Kuntaraksa
P084	Socioeconomic Outcomes With Ribociclib in Patients With HR+, HER2- Advanced Breast Cancer (ABC) in UK Real-world Settings	Peter Hall
P085	Target axillary dissection in cN2 breast cancer patients after neoadjuvant chemotherapy. Preliminary results	Amparo García
P086	5 years case series review of the impact of Combined Reverse abdominoplasty flap in reconstruction of anterior chest wall defects post extensive mastectomies	Ibrahim Sallam
P087	Therapeutic comparison of two oral chemotherapy regimens indicated in advanced breast cancer (Multicenter study of 74 cases)	Amina Bouguettaya

Radiotherapy/IORT

P088	The evaluation of the 21-gene Breast Recurrence Score assay as a prognostic factor for locoregional recurrence in early breast cancer treated by lumpectomy and intraoperative radiotherapy only	Michelle Leviov
P089	Impact of radiation on immediate breast reconstruction: A retrospective single institution cohort study	Kitwadee Saksornchai
P091	Deep inspiration breath hold in post-operative radiotherapy for right breast cancer	Mariacarla Valli
P093	Impact of breast size on partial breast radiotherapy planning and short term outcome: a single institution experience at University Hospital of North Midlands (UHNM) UK	Shahid Gilani
P094	Hypo-fractionated radiotherapy in early breast cancer patients –Local control ,long term results	PETROS GRIGOROPOULOS
P095	Ultra-hypofractionated adjuvant radiotherapy in very elderly patients with early breast cancer	PETROS GRIGOROPOULOS
P096	Accelerated Partial Breast Irradiation Versus Whole Breast Irradiation Using 3-Dimensional Conformal External Beam Radiation Therapy: Long term outcomes data of a study from India	Budhi Singh Yadav
P097	Hypofractionated radiotherapy after neoadjuvant chemotherapy in Breast Cancer: Safety, feasibility, and early outcomes	Ghada Abdessatar
P098	Adjuvant radiotherapy after radical surgery and immediate breast reconstruction	Marta Ciauriz Gortari
P099	Postoperative cosmetic outcome of intraoperative radiotherapy in comparison to whole breast radiotherapy in early stage breast cancer; A retrospective cohort study	nahid nafissi
P100	Thyroid dose distribution during hypofractionated radiotherapy for breast cancer	Mouna Ben Rejeb
P101	Clinical feasibility of breast tumor bed irradiation with the Hybrid magnetic resonance linear accelerator 1.5 T MR-Linac	Zohra Mazouni
P102	Ultra hypofractionated radiotherapy after breast conservative surgery : analysis of acute skin toxicity	Mouna Ben Rejeb
P103	PRE-ACT: Prediction of Radiotherapy side Effects using explainable AI for patient Communication and Treatment modification	Tim Rattay
P104	Hypofractionated radiotherapy in triple negative breast cancer: Does molecular subtype impact radiotherapy outcomes ?	Meriem Skouri

P105	Internal mammary chain irradiation in breast cancer patients: Which patterns of practice between controversial benefit and challenging dosimetry?	Meriem Skouri
P106	De-escalation of radiation therapy after primary systemic therapy in non-metastatic breast cancer: patterns of recurrence from a real-world single-centre cohort of patients	Icro Meattini
P107	Evaluation of Patient Satisfaction with Breast Q after Post-mastectomy Hypofractionated Radiotherapy with Immediate Implant Reconstruction	Bahadir Gulluoglu
P108	Should we delineate brachial plexus in hypofractionated locoregional breast radiotherapy to reduce the risk of brachial plexopathy?	Rim Moujahed
Neoadjuvant (pre-operative) therapy		
P109	Addition of platinum analogues to neoadjuvant chemotherapy improving pathologic complete response among triple negative breast cancer patients. Real World Evidence	CLAUDIA ARCE-SALINAS
P110	The predictive role of SHARP1 and SHARP2 transcription factors in patients with breast cancer upon neoadjuvant chemotherapy	Kayhan Ozdemir
P111	A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP vs ddAC-THP in high-risk HER2-positive early stage breast cancer (DESTINY-Breast11)	Nadia Harbeck
P112	Clinicopathological factors for predicting tumor response in hormonal positive/HER2-negative breast cancer patients receiving neoadjuvant chemotherapy	Pirada Yincharoen
P113	MRI Patterns in the evaluation of pathological response after Neoadjuvant Endocrine therapy in ER+/HER2- Breast Cancer and Implications on Surgical Planning	Bothaina Nakad
P114	Characteristics of residual tumor after neoadjuvant chemotherapy (nact) may predict outcomes in patients with triple negative breast cancer (tnbc)	Mona Frolova
P115	OlympiaN: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib with or without durvalumab in patients with <i>BRCAm</i> early-stage HER2-negative breast cancer	Judith Balmaña
P116	Axillary residual disease in patients with positive sentinel node after neoadjuvant treatment according to tumor subtype	Marta Ciaurriz
P117	Axillary residual disease after neoadjuvant treatment according to disease burden in the sentinel lymph node biopsy	Marta Ciaurriz
P118	Efficacy of platinum-based neoadjuvant chemotherapy in early triple-negative breast cancer according to germline <i>BRCA</i> mutation	Soong June Bae
P119	Recurrence Score [®] result by the 21-gene assay before and after systemic neoadjuvant chemotherapy in patients with HR+ HER2- breast cancer.	Carlos Hagen
P120	Cardiac safety of pertuzumab, trastuzumab and standard chemotherapy as neoadjuvant treatment for HER2 positive breast cancer: real world data from NeoPower trial	Fabio Canino
P121	Primary Chemotherapy with Bevacizumab for Locally Advanced Triple Negative Breast Cancer	John Carpenter
P122	Clinical impact of fine needle aspiration cytology on sentinel node biopsy after preoperative chemotherapy for core needle biopsy-proven metastatic lymph nodes	Rikiya Nakamura
P123	Optimal Regimen of Neoadjuvant Systemic Therapy for HER2 Positive Early Breast Cancer	Chiao Lo
P124	The Study of subtype conversion after neoadjuvant chemotherapy in locally advanced breast cancer	Kris Virojanapa
P125	Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study	Wilbur Pan



P126	Pathological complete response after neoadjuvant chemotherapy in patients with HER2 low and HER2 0 early breast cancer (eBC) – experience from Institute for Oncology and Radiology of Serbia (IORS)	Ognjen Djurmez
P127	Efficacy and safety of trastuzumab biosimilar Abdi Ibrahim in the neoadjuvant setting for HER2 positive breast cancer: about 40 cases	Nadia Nèche
P128	Intraoperative Ultrasound Guided Tailored Axillary Surgery After Neoadjuvant Therapy in Breast Cancer Patients	Guldeniz KARADENIZ CAKMAK
P129	Neoadjuvant chemotherapy in ER-positive Early Breast Cancer: predictive factors of response and outcome	Nassima KOUADRI
P130	Recurrence rate following pCR in patients receiving NACT	Anuja Raniwala
P131	Real World Evidence of the Impact at Neoadjuvant Chemotherapy Treatment on the Prognosis of Patients with Early Breast Cancer	Marcelo Antonini
P132	(Trial in Progress) A phase 2, open-label, randomized multicenter trial to evaluate neoadjuvant lasofoxifene in molecularly-selected HR+/HER2- Clinical Stage 2/3 breast cancer	David Portman
P133	Immunohistochemical expression of estrogen receptors after neoadjuvant chemotherapy in breast cancer	Karim Ben Hamida
P134	Neoadjuvant Therapy in Non-Metastatic Breast Cancer in Kurdistan, Iraq	Karez Namiq
P135	Response to neoadjuvant chemotherapy in HER2-positive breast cancers : a single-centre study	Karim Ben Hamida
Health politics/Guidelines		
P136	Improving incentives to BRCA testing through amending health insurance regulation – a critical analysis	Wai Chan
P137	PERSONA study: Optimization of the value-based healthcare as for the follow-up of women with breast cancer- A portrait of breast cancer survivor's follow-up in Portugal	Catarina Abreu
P138	Evaluation of germline mutation in high risk breast cancer cohort: compliance with NCCN 2023 v.1 testing criteria	Ava Kwong
P139	Factors influencing underutilization of genetic clinic services by surgeons and breast cancer patients in Low-Middle Income countries- A retrospective cross-sectional study	Lubna Vohra



Predictive and prognostic factors		
P140	Menopausal breast cancer: Bone Mineral Density (BMD) and prognostic factors	Maxim Izquierdo
P141	Prognostic factors breast cancer after pregnancy	Maxim Izquierdo
P142	Functional impact of a rare germline TP53 variant (NM_001126114.2, c.1018A>G, p.N340D) in a family with the Li-Fraumeni-like syndrome	Daniel Wilhelm Olivier
P143	Kinetics of Ejection Fraction Decline as A Predictive Factor for Cardiotoxicity in Trastuzumab-treated Early Breast Cancer Patients: Single Institution Experience	Omnia M. Korani
P144	The Effect of Progesterone Receptor Expression Level to Predict Prognosis of Estrogen Receptor Positive/ HER2 Negative Young Breast Cancer: A Single-Center Prospective Cohort Study	Youngji Kwak
P145	Postpartum breast cancer diagnosed within 10 years of last childbirth is a prognostic factor for distant metastasis – analysis of lymphovascular invasion relating factors	Asumi Iesato
P146	Risk factors of breast cancer recurrence in pathologic complete response achieved patients following neoadjuvant chemotherapy	Joon Young Choi
P147	Clinical, pathological, and prognostic features of male breast cancer. A multicenter study	Francesca Accomasso
P150	Psychological distress during hospitalization for breast cancer patients in the outbreak, post-peak, and normalization stages of the COVID-19 pandemic	Xin Zhao
P151	The prediction of Oncotype DX risk group using clinicopathologic factors in patients with HR+/HER2- early breast cancer	Ran Song
P152	The impact of the TailorX and RxPonder studies and the use of Oncotype Dx in clinical practice: A single Breast Cancer Center experience	DIMITRIOS NASIKAS
P153	The clinical impact of Prosigna [®] assay for adjuvant treatment in early-stage Thai breast cancer patients: single centre, real-life practice	Nuanphan Polchai
P154	Characteristics and prognosis of BRCA-associated breast cancers: Results from a single-center observational study in Thailand	Manunya Phattaravittakon
P156	Usefulness of pretreatment 1CTP levels as prognosis prediction	Mio Yasukawa
P157	MammaPrint 8-year follow up results in patients with early breast cancer from a single-center Italian cohort study	Daniele Generali
P158	PONDx Aragon: First spanish prospective study evaluating the impact of the 21-gene test on real praxis for N1 patients after RxPONDER results	Carlos Hagen
P159	Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio are not predictive of Pathologic Complete Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer	Inês Soares de Pinho
P162	Contralateral Breast Cancer in BRCA 1 vs 2 Mutation Carriers	Antonia Girardi
P163	Mutation profiling of NOTCH signaling pathway in primary breast cancer among Indian population	Pranay Tanwar
P164	Breast cancer patients aged 70 and over: clinical characteristics, treatment, and prognosis	Ji Hye Kim



P165	Distance from epicenter of tumor to nipple in predicting regional lymphnode metastasis	Tanet Chatmongkonwat
P166	Budget impact of MammaPrint® in Patients with primary hormone receptor-positive, HER2-negative and non-metastatic early-stage breast cancer in France	Jelle Klinkhamer
P167	Prediction of Axillary lymph node metastasis by Tumor to breast ratio in breast cancer	Wongpipat Phool
P168	OncotypeDX RS new TAILORx cut-offs: omitting Chemotherapy in more patients aged >50 years with Early Breast Cancer	Christos MarKopoulos
P169	Clinical outcomes in patients (pts) with estrogen receptor (ER)+ stage I breast cancer (BC) and Recurrence Score (RS) 26-30: Real-world data	Ofer Rotem
P171	Do Tumor Infiltrating Lymphocytes and Programmed Cell Death Ligand -1 have a Predictive and Prognostic Role in Advanced Triple Negative Breast Cancers – Results of a Study from a Developing Country	Vishvak Chanthar K M M
P172	Different incidence of brain metastasis according to HER2 expression level in patients with triple negative breast cancer	Yumiko Koi
P173	Should positive surgical margin involvement of in situ carcinoma of invasive breast cancer after breast conserving surgery be treated with additional resection?	Yukiko Yoshii
P174	Role of Age on Biomarker Status and Clinical Feature in Early Breast Cancer at Dr. Saiful Anwar Hospital, Malang- Indonesia	Shinta Oktya Wardhani
P175	Characteristics and Survival Outcomes of Breast Cancer Patients Discussed at Molecular Tumor Board of European Institute of Oncology	Edoardo Crimini
P304	Prognostic significance of ki-67 expression in Breast Cancer Patient	Namra Urooj

Surgery/Sentinels/DCIS

P176	Is the ≥1-cm width of resection margin in phyllodes tumor necessary to reduce recurrence?	Nattakarn Changchit
P177	Prepectoral versus subpectoral implant-based breast reconstruction: A systemic review and meta-analysis.	Edvin Ostapenko
P178	Breast reconstruction with resorbable scaffold and fat	Dimitrios P. Mastorakos
P179	Breast molecular subtypes predict the local recurrence after primary surgery of breast cancer	Piratthima Vachiraparakarsakul
P180	An associated of suspicious lymph node by ultrasound/mammogram and sentinel lymph node followed by ultrasound guide clip-node placement in Early Breast cancer patient	Supanat Kaeosuwan
P182	Factors Influencing Breast Cancer Resection Volumes and their Impact on Treatment Outcome: Multi-center Prospective Study (FIBRATIO) – Study Protocol and Preliminary Results	Ulla Karhunen-Enckell
P183	A Pivotal Phase III Randomized Clinical Trial to Evaluate the Safety and Efficacy of the Fluorescent Imaging Agent PD G 506 A for the Real-time Visualization of Cancer During Breast Conserving Surgery	Eleftherios Mamounas
P184	Unsatisfactory cosmetic results after oncoplastic breast-conserving surgery	Idam de Oliveira-Junior
P185	Long-term impact of radiotherapy on the clinical and patient-reported outcomes of immediate breast reconstruction in a UK population-based cohort study	Shelley Potter
P186	Confirmatory study of nanoparticle-assisted axillary staging in breast cancer patients who received neoadjuvant chemotherapy: expanded indication and reduced axillary intervention	Tao He

P187	Comparison of long term oncologic outcome of sentinel lymph node mapping methods, dye-only versus dye and radioisotope in breast cancer following neoadjuvant chemotherapy	Changjin Lim
P188	The accuracy of the upstaging prediction model for ductal carcinoma in situ: a retrospective comparative study	Ching-Wen Chiu
P189	Impact assessment of sentinel lymph node core needle biopsy guided by ultrasound for node-positive breast cancer patients	George Kinoglou
P190	Volume Replacement with Acellular Dermal Matrix Versus Absorbable Mesh after Breast-Conserving Surgery: A Randomized Controlled Trial	Manunya Phattaravittakon
P191	Skin-sparing or nipple-sparing mastectomy with one-stage or two-stage reconstruction: analysis of early outcomes and patient's satisfaction	Angela Gurrado
P192	Ptotic versus non ptotic breasts in nipple-sparing mastectomy and immediate prepectoral breast reconstruction	Edvin Ostapenko
P193	Intraoperative specimen digital breast tomosynthesis as predictor of resection margin status in breast conserving surgery for breast cancer - first year experience	david pavlišta
P194	Single-incision endoscope-assisted breast-conserving surgery and sentinel lymph node biopsy: A prospective cohort study (the SINA-BCS study)	Shan Lu
P195	Prophylactic Risk Reducing Mastectomy (PRRM): A set practice or catch 22 in low middle income countries. A single-center prospective cohort study	Lubna Vohra
P196	Breast Textured Implants Determine Early T-helper Impairment: BIAL2.20 Study	Oreste Claudio Buonomo
P197	Benign and Borderline Phyllodes: Management and Follow-Up	Georgios Kinoglou
P199	Management and Outcomes of Very Young Women (≤ 35 Years) with Breast Cancer treated in a single Institution	Lorenzo Scardina
P200	Sentinel lymph node biopsy in the elderly breast cancer patient – 10 year experience from a Swiss tertiary center	Martin Heidinger
P201	Patient reported outcome measures in patients who have undergone chest wall perforator flaps (cwpfs) for breast reconstruction	Ishita Laroia
P202	Targeted axillary dissection after neoadjuvant chemotherapy: a multicenter prospective study of feasibility and safety	Andrea Villasco
P203	Comparing the combine flap fixation and Harmonic scalpel technique with the Harmonic scalpel alone in reducing seroma formation after mastectomy in breast cancer patient: A pilot study for a RCT	Nawin Kuntaraksa
P204	SPECT/CT lymphoscintigraphy can accurately localize the sentinel lymph nodes and the clipped node in breast cancer patients undergoing targeted axillary dissection after neoadjuvant chemotherapy	Burak Celik
P205	Modified pectoral nerve block conducted Intraoperatively by surgeons Is effective for postmastectomy pain control: A prospective double-blinded randomized control trial	Waraporn Imruetaicharoenchoke
P207	Postoperative outcomes of replacement technique using the acellular dermal matrix as filler for BCS patients	Jun Tae Park
P208	Contrast-enhanced ultrasound using intradermal microbubble sulfur hexafluoride for identification of sentinel lymph nodes during breast cancer surgery: a clinical trial	Marco Materazzo
P209	Factors affecting drain indwelling time after axillary dissection in patients with breast cancer	Barsha Pantha

P210	Radiological and pathological predictors of post-operative upstaging to invasive ductal carcinoma and lymph nodes metastasis in patients preoperatively diagnosed with breast ductal carcinoma in situ	Marco Pellicciaro
P211	Surgical treatment for elderly patients with ductal carcinoma in situ. Is it still a safety and valid option?	Marco Pellicciaro
P212	Development of a deep learning based model for guiding the dissection plane of robot endoscopy breast surgery	Jeea Lee
P213	The impact of chemotherapy on prepectoral breast reconstruction	DANTE PALLI
P214	The role of locoregional treatment in non-progressive de novo multi-metastatic breast cancer, a randomized controlled trial	Ramesh Omranipour
P215	Absent post-treatment changes in negative sentinel lymph nodes and regional recurrence in initially node positive breast cancer patients	Nina Pislar
P216	Therapeutic Mammoplasty: Assures conservation, Elevates lifestyle. Data from the largest Asian cohort	Amit Bagdia
P217	Upstaging and lymph node metastasis rate in patients with ductal carcinoma in situ who received mastectomy regarding the necessary of sentinel lymph node biopsy	Jisoo Jang
P218	Perforator Flaps: Can they be an elixir for the oncoplasty woes of developing nations?	Amit Bagdia
P219	Early experience with Magtrace [®] for sentinel node biopsies in two Scottish breast cancer units	Chia Kong
P220	Early post-operative outcome of pre-pectoral implant-based immediate total breast reconstruction with Vicryl mesh - An experience from a low-middle income country	Safna Virji
P221	Using an ultra-low dose of superparamagnetic iron oxide for sentinel lymph node detection in breast cancer patients - the MAGSNOW feasibility study	Nushin Mirzaei
P222	Systemic inflammation markers as predictors of axillary clearance: a multicenter analysis on 1274 nodal positive breast cancer patients undergoing primary systemic treatment	Maria Luisa Gasparri
P223	Effect of margins in recurrence rate following breast conserving therapy	Liyang Wang
P224	Quality of life and patient outcomes after oncoplastic breast conservation versus nipple sparing mastectomy and immediate breast reconstruction	EIRINI ANGELIDOU
P225	Impact Of Oncoplasty in Increasing Breast Conservation Rates Post Neo-Adjuvant Chemotherapy	C. B Koppiker
P226	Indocyanine green fluorescence imaging for real-time detection of breast cancer tumors: a systematic review	C Florin Pop
P227	Prospective Randomized controlled trial evaluation safety of Breast conserving surgery in multicentric/multifocal breast cancer	Namra Urooj
P228	Targeted Axillary Dissection post primary chemotherapy: data analysis from a single multidisciplinary unit in South Africa	Carol-Ann Benn
P229	Assessment of Complication rates in patients undergoing Direct to Implant reconstruction in A single Multidisciplinary unit in Johannesburg South 2022	Carol-Ann Benn
P230	Breast reconstruction: recurrence in patients with mastectomy and immediate breast reconstruction	Marta Ciaurriz Gortari
P231	Prepectoral versus subpectoral single stage breast reconstruction after conservative mastectomy for breast cancer: surgical and oncological outcomes	Lorenzo Scardina
P232	A study to evaluate the safety and utility of targeted axillary dissection using Guiding-Marker System	Yuka Endo
P233	Early outcomes of volume replacement using injectable acellular dermal matrix for oncoplastic breast conserving surgery	Eun Hwa Park

P235	The value of palpation,US and NMR in staging of axilla in patients with breast cancer in order to avoid unnecessary ALND	Zvezdan Maksimovic
P236	Immediate breast reconstruction as a day case procedure and impact of COVID-19 pandemic	Nidhi Garg
P237	Analysis of factors with impact on short stay surgery for patients operated for breast cancer during COVID 19 pandemic	Zvezdan Maksimovic
P238	Is BCT safer than Mastectomy for the treatment of early breast cancer?	Marco Mele
P239	Multi-institutional Experience of Modified Lateral Intercostal Artery Perforator (LICAP) Flap Operation: Surgical and Patient Reported Outcomes (PROMs)	Ibrahim Sallam
P240	Computerized Quantification of Tumor Infiltrating Lymphocyte (TIL) as a prognostic and predictive factor in ductal carcinoma <i>in situ</i> : Results from the UK/ANZ DCIS randomized trial	Mangesh A. Thorat
P241	Skin reducing mastectomy and immediate hybrid breast reconstruction using combination of acellular pericardium matrix and deepithelialized dermal flap in patients with hypertrophic and ptotic breasts	Dimitrios Varvaras
P242	Use of Acellular Pericardial Biological Mesh for Prepectoral and Dual Plane Prosthetic Breast Reconstruction Following Conservative Mastectomies	Dimitrios Varvaras
P243	Is the indian population ready for acosog z0011 protocol?	Abinaya R Nadarajan
P244	Rates of lymphoedema and complications using a vessel sealing device in axillary node clearance compared to standard technique in a single tertiary centre	Primeera Wignarajah
P245	Apocrine breast carcinoma. a single institution experience and literature review	Nikolaos Salemis
P246	A comparative study between round block technique and standard wide local excision in patients with breast cancer	mohamed ibrahim
P247	Radiofrequency as a method of localizing occult breast lesions	Mariam Malik
Other		
P248	Evaluation of potential factors related to chemotherapy-induced nausea and vomiting (CINV) among Chinese breast cancer patients: individual patient data analysis	Winnie Yeo
P249	IMPACT of COVID-19 pandemic on breast cancer diagnosis and treatment	Ridhi Ranchor
P250	Deep learning-based breast lesion localization and segmentation in 3d automated breast ultrasound (3d abus) images	Sarun Lertsatittanakron
P251	Real-world experience with CDK4/6 inhibitors for metastatic HR+/HER2- breast cancer at a single cancer center	Marijana Milovic - Kovacevic
P252	Comparison of the Effectiveness of Complex Decongestive Therapy Components in the Treatment of Upper Extremity Lymphedema Associated with Breast Cancer	Seray Eken Özdilek
P253	ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER+/human epidermal growth factor receptor 2 (HER2)- breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study	Scott Wirth
P255	Breast cancer surgery with 'pecs block' technique in the oldest old	Laura Roveda
P256	Quality of life in breast cancer patients, preoperatively and postoperatively. Methods of influencing the quality of life.M. M.Valcan university of oradea, faculty of medicine and pharmacy , romania	Mariana Mirela VALCAN
P257	Impact of electronic Patient Reported Outcomes for symptom monitoring on unplanned consultations and hospitalizations in cancer patients receiving systemic therapy	Andreas Trojan
P258	Breast cancer and endometriosis: correlation between different type and stage. A preliminary study	Valentina Marsella

P259	Immune-mediated implications of SARS-CoV-2 in breast cancer patients	Vanya Mitova
P260	Real World Data Analysis of Palbociclib plus endocrine therapy in first-line in ibero-american premenopausal women with Luminal Advanced Breast Cancer	Maria Victoria Costanzo
P261	Review of mammogram-led follow-up outcomes in Early Breast Cancer patients	Sohail Anjum Khan
P262	How patients prioritize features of different potential treatment pathways in early breast cancer: a best-worst scaling study	Christian Jackisch
P263	Patients' perspectives on treatments for HR+/HER2- early breast cancer: developing a quantitative patient preference survey	Nadia Harbeck
P264	The Comparison Outcome of Implant-based Breast Reconstruction with ADM, Non-ADM and TiLOOP Reconstruction in Breast Cancer Patients: A Case Series	Warachya Arjhan
P265	Cryoablation in Breast Cancer Care - an analysis from a Single Multi-Disciplinary Unit in Southern Africa	Carol Benn
P266	Cryoablation with endocrine therapy for clinical stage I/II, ER+, HER2-, invasive breast cancer in patients with omission of surgical axillary staging	José María Oliver Goldaracena
P267	Percutaneous cryoablation treatment of early and low risk breast cancer. An effective alternative to surgical treatment	María José Roca Navarro
P268	Impact of the 2020 COVID-19 lockdown in Switzerland on physical activity in patients with early breast cancer under aromatase-inhibitor therapy. A subanalysis of the SAKK 95/17 WISE trial	Friedemann Honecker
P269	Real world experience with Everolimus in the management of metastatic breast cancer ER positive/HER2 negative	Alexandra Garcilazo Reyes
P270	Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?	Kerstin Wimmer
P271	The impact of extraordinary situation such as the war on tumor characteristics and time before the start of treatment in patients with non-metastatic breast cancer (BC)	Tetiana Tarasenko

Survivorship issues

P273	The lived experiences of telehealth system use among women with breast cancer.	Nizar Bin Zainal Mohamad
P274	Association between tamoxifen and incidence of osteoporosis in Korean patients with ductal carcinoma in situ	Chang Ik Yoon
P276	Patients' Expectations for Follow-Up of Early Breast Cancer: A Cross-Sectional Study	Iazaros Papadopoulos
P277	Sick leave and predictive factors for sick leave at 12 months after breast cancer surgery in the randomized controlled physical activity trial (PhysSURG-B)	Jenny Heiman
P278	Early Integrated Rehabilitation Helped Breast Cancer Patients to Start Healthy Lifestyle– A Comparison Between the Intervention and Control Group in a Prospective Study	Mateja Kurir Borovcic
P279	A patient survey evaluating COVID-19-induced changes in follow-up of patients with EBC: opportunities for enhanced evidence-based practice?	Ana-Alicia Beltran-Bless
P280	How often do breast cancer patients seek traditional Chinese medicine in North China?	Jinnan Gao
P281	The effect of Chinese culture on family planning of Childbearing age women with breast cancer in North China	Jinnan Gao
P282	Survival outcomes after neoadjuvant chemotherapy according to the axillary status and tumor subtype	Marta Ciáurriz
P283	Overall survival of patients treated for breast cancer: about 124 cases	HANANE BENZEBIDA



P284	The relation of individual psychological traits and coping strategies to depression and anxiety levels among non-metastatic breast cancer patients	Spyridoula Karveli
P285	Effect of socio-demographic factors on patient reported outcomes in Indian breast cancer patients	Anushree Vartak
P286	Quadruple Negative Breast Cancer (QNBC): outcomes in survival and comparison with the classic phenotype of TNBC	SOFIA KOURA
P287	Overall survival after neoadjuvant chemotherapy depending on pathological response and tumoral phenotype	Marta Ciaurritz Gortari
P288	Is it safe to discontinue long-term trastuzumab containing therapy after radiological complete response (rCR) in metastatic HER-2 positive breast cancer (MBC)?	Marina Calamac
P289	Retrospective study of pregnancy outcome after breast cancer	Akiyo Yoshimura
P290	Life without a breast : The underreported symptoms after radical mastectomy	Molka Mezghani
P291	Evolving strategies for the routine follow-up of patients with early breast cancer and the impact of COVID-19: a survey of healthcare providers	Ana-Alicia Beltran-Bless
Diagnostics		
P292	Cell-free DNA (cfDNA) profiling using Guardant360 in Japanese metastatic breast cancer patients	Masahiro Kawashima
P293	Classification of abnormal findings on dedicated breast PET for prediction of malignancy	Shinsuke Sasada
P294	Prediction of tumor microenvironment functionality using ¹⁸ F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography for early-stage triple negative breast cancer	Yuri Kimura
P295	Evaluation of Sentinel Lymph Node by sonography	Toshio Hashimoto
P297	Accuracy of Vacuum Assisted Excision in minimizing overtreatment of breast lesions with uncertain malignant potential (B3 lesions) from a single institution	Masuma Sarker
P298	Contrast-enhanced mammography(CEM) with magnetic tracer as an alternative to MRI	Carol-Ann Benn
P299	Utility of Positron Emission Tomography in staging patients with recurrent breast cancer	Raouef Ahmed Bichoo
P300	Evaluation of preoperative breast MRI findings in breast cancer patients	Maria Matiatou
P302	The link between IL-6 rs1800797 and STAT3 rs4796793 Polymorphisms with breast cancer susceptibility in Bangladeshi women	Mohammad Safiqul Islam
P303	Clinical, anatomo-pathological and molecular specificities of breast cancer in women >70 years old about 53 cases in Eastern Algeria. (Monocentric study)	Amina Bouguettaya